Critical Transplant Medications Recalled Due to Empty Capsules

Global Pharmaceutical Company Warns of Fatal Risks for Organ Recipients

Astellas Pharma launched an emergency recall of two essential transplant medications on December 26, 2024, after discovering potentially empty capsules in specific lots of Prograf and Astagraf XL. The manufacturing defect affects immunosuppressive medications crucial for preventing organ rejection in transplant patients. The company identified two specific lot numbers set to expire in March 2026, prompting immediate action to prevent potentially fatal consequences for heart, liver, kidney, and lung transplant recipients.

5 Key Points

• Empty capsules were discovered in Prograf 0.5 mg and Astagraf XL 0.5 mg medications.
• The recall affects specific lot numbers 0E3353D and 0R3092A with March 2026 expiration dates.
• Medications prevent organ rejection in transplant patients.
• Heart transplant patients face the highest risk due to a lack of alternative treatments.
• Astellas Pharma established a direct hotline for healthcare providers and pharmacies.

Manufacturing Defect Threatens Patient Safety

Astellas Pharma’s discovery of empty capsules in critical transplant medications has sparked immediate concern across the medical community. The manufacturing oversight affects a specific number of immunosuppressive medicines prescribed to prevent organ rejection after lifesaving transplant procedures. Quality control failures at this level raise particular alarm because these medications form the cornerstone of post-transplant survival. Transplant specialists emphasize that even a single missed dose could trigger a catastrophic immune response, leading to organ failure. The affected lots, manufactured with expiration dates of March 2026, have been distributed through standard pharmaceutical supply chains, prompting an urgent nationwide alert to healthcare providers and pharmacies.

Recalled Medications

The recall specifically targets:

1. Prograf 0.5 mg capsules
   • Lot Number: 0E3353D
   • Package: 100-count bottles
   • Expiration: March 2026
   • Usage: Prescribed after heart, liver, kidney, or lung transplants
2. Astagraf XL 0.5 mg capsules
   • Lot Number: 0R3092A
   • Package: 30-count bottles
   • Expiration: March 2026
   • Usage: Specifically prescribed for kidney transplants

Get a free legal case review today

Did you develop any of the following injuries after being exposed to Fire Fighting Foam (AFFF)? * Choose one Ulcerative Colitis Kidney Cancer Pancreatic Cancer Testicular Cancer Prostate Cancer Bladder Cancer Thyroid Disease Liver Cancer Non-Hodgkin's Lymphoma None of the above Were you exposed to Fire Fighting Foam (AFFF)? *

YesNo

Which medication(s) did you take during your pregnancy? * Choose one Tylenol Acetaminophen Alka-Seltzer Coricidin Dayquil Excedrin FluTherapy Midol Mucinex Nyquil Panadol Robitussin Sinex Sudafed Theraflu Other Medication(s) Was your child diagnosed with Autism, ADHD or another condition? * Choose one Autism/Autism Spectrum Disorder (ASD) Attention Deficit Hyperactivity Disorder (ADHD) Asperger’s Syndrome Kanner’s Syndrome Childhood Disintegrative Disorder Pervasive Developmental Disorder Other Medical Condition How old was your child at the time of diagnosis? *

Under 18 years old18+ years old

Did the accident occur within the last 2 years? *

YesNo

First Name *

Last Name *

Email Address *

ZIP Code *

Phone Number *

What is your case type? * Choose one -------------------- Asbestos Baby Formula Camp Lejeune Clergy Abuse CPAP Elmiron Exactech Firefighting Foam FTX Exchange Hair Relaxer Hernia Mesh Paraquat PFAS Roundup Sex Abuse Social Media Talcum Powder Tepezza Tylenol -------------------- Birth Injury Car Accident FELA Medical Malpractice Motorcycle Accident Slip and Fall Trucking Accident Uber & Lyft Rideshare Workplace Injury Weight Loss Wrongful Death -------------------- Something Else

Human Verification *

I understand and agree that (a) submitting this form does not create an attorney-client relationship, (b) I am not already represented by an attorney for this matter, (c) the information I submit will be shared with a law firm, and (d) I have read and accepted the terms and conditions of the Privacy Policy, Terms of Service and Legal Disclaimer. Further, I consent to being contacted by a law firm or its agent after submitting this request.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Critical Impact on Heart Transplant Recipients

Heart transplant patients face the highest risk from this recall due to the absence of alternative life-sustaining treatments. Unlike kidney transplant patients who can access dialysis as a backup option, heart transplant recipients depend entirely on these immunosuppressive medications to prevent organ rejection. The consequences of missed doses prove particularly severe for heart transplant patients, as organ rejection can progress rapidly without proper immunosuppression. Astellas Pharma’s recall notice explicitly acknowledges that for heart transplant patients, the consequences of taking empty capsules could prove fatal. The pharmaceutical company has established direct communication channels with healthcare providers to manage patient transitions to unaffected medication lots, emphasizing the time-sensitive nature of this replacement process.

Immediate Actions Required

Pharmacies and wholesalers holding the affected lots must immediately quarantine these products and contact Astellas Pharma through their dedicated recall hotline. The urgency of this recall requires healthcare providers to identify and contact all patients currently using the affected lots to arrange alternative medication supplies. Medical professionals stress that patients should not discontinue their current medication without direct guidance from their transplant team, as any interruption in immunosuppressive therapy carries significant risks. Patients showing any signs of organ rejection, including fever, pain near the transplanted organ, or unexpected changes in health status, require immediate medical evaluation. The FDA’s MedWatch program serves as the central reporting system for adverse events related to this recall, creating a standardized channel for tracking any complications that may arise.